



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/725,373		
		Filing Date	December 3, 2003		
		First Named Inventor	Jeffrey SCHLOM et al.		
		Group Art Unit	1644		
		Examiner Name	Marianne Nea DiBriano		
Sheet	1	of	2	Attorney Docket Number	38163-0197

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
Mo	B01	WO	96/26271	—	Schlom et al.	8/29/1996	—	


Examiner Signature		Date Considered	12/9/05
-----------------------	--	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/725,373
		Filing Date	December 3, 2003
		First Named Inventor	Jeffrey SCHLOM et al.
		Group Art Unit	1644
		Examiner Name	Marianne Man DiBriano
		Attorney Docket Number	38163-0197
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MO	B02	CHEN, Y., et al., Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonist and TCR antagonism with or without partial activation. J. Immunol., 157: 3783-3790 (1996).	
MO	B03	JAMESON, S.C., et al., T cell receptor antagonists and partial agonists. Immunity, 2:1-11 (1995).	
MO	B04	TSANG, K.Y., et al., Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87:982-990 (1995).	
MO	B05	ZAREMBA, S. et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Research. 57:4570-4577 (1997).	
MO	B06	RUPPERT J. et al., "Class I MHC-Peptide Interaction: Structural and Functional Aspects", Behring Institute: Mitteilungen, July 1, 1994, p. 48-60, no. 94, XP000604845	
MO	B07	DENIS HUDRISIER et al., "Binding of Viral Antigens to Major Histocompatibility Complex Class I H-2D ^b Molecules Is Controlled by Dominant Negative Elements at Peptide Non-anchor Residues", The Journal of Biological Chemistry", 1996, pp. 17829-17836, Vol. 271, No. 30	
MO	A08	LUIS JAVIER SIGAL et al., "Role of Non-Anchor Residues of D ^b -Restricted Peptides in Class I Binding and TCR Triggering", Molecular Immunology, 1996, pp. 1323-1333, Vol. 33, No. 17/18	
MO	A09	LUIS J. SIGAL et al., "D ^b -Binding Peptides from Influenza Virus: Effect of Non-Anchor Residues on Stability and Immunodominance", Molecular Immunology, 1995, pp. 623-632, Vol. 32, No. 9	
MO	A10	CATARINA E. HIOE et al., "Alterations of a Dominant Epitope of Lymphocytic Choriomeningitis Virus Which Affect Class I Binding and Cytotoxic T Cell Recognition", Molecular Immunology, 1995, pp. 725-731, Vol. 32, No. 10	

Examiner Signature	<i>Marianne DiBriano</i>	Date Considered	12/9/05
--------------------	--------------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.